Objective: Deutetrabenazine is a deuterated formulation of tetrabenazine. The aim of this systematic review is to describe the efficacy, tolerability and safety of deutetrabenazine for the treatment of tardive dyskinesia (TD).
| INTRODUCTION
Deutetrabenazine (SD-809) is a reversible vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the US food and drug administration (FDA) on 30 August 2017 for the treatment of adults with tardive dyskinesia (TD), and represents the second pharmaceutical agent approved in the US for this purpose, with valbenazine having been approved in April 2017.
1,2 Like tetrabenazine, 3 deutetrabenazine is also approved for the treatment of chorea associated with
Huntington's disease. 1 An additional indication under development for deutetrabenazine is Tourette syndrome. 4 Tardive dyskinesia has long been thought to be a generally irreversible consequence of the use of dopamine receptor blocking agents.
Dopamine receptor blocking agents include antipsychotic medications
used for the treatment of psychiatric disorders and antiemetic medications such as metoclopramide used for symptomatic gastroesophageal reflux in patients who fail to respond to conventional therapy. TD is characterised by involuntary, repetitive, purposeless movements of typically the tongue, jaw, lips, face, trunk, upper extremities and lower extremities, and these movements can be stigmatising. 5 TD is common;
in a meta-analysis of 41 studies published since 2000, the overall mean TD prevalence in patients exposed to antipsychotics was 25.3%, with a lower prevalence for those receiving second-generation antipsychotics vs first-generation antipsychotics, with prevalence rates of 20.7% and 30.0%, respectively. 6 Lower TD prevalence (7.2%) was found among patients receiving second-generation antipsychotics who had never been exposed to first-generation antipsychotics. 6 It is anticipated that with the expansion of the use of antipsychotics beyond schizophrenia and bipolar disorder to also include persons with major depressive disorder that the number of people at risk to develop TD will continue to increase.
In the past, suggested treatments for TD have been largely ineffective or limited. 7, 8 Although based on limited data, tetrabenazine has emerged as a preferred "off-label" treatment option for TD. [8] [9] [10] [11] Problematic are obstacles to use, including tetrabenazine's pharmacokinetic profile requiring frequent dosing, and safety and tolerability concerns that include drowsiness, Parkinsonism and treatment-emergent depression (including suicidality). 12 These limitations were the motivation behind the development of alternatives to tetrabenazine that ideally would retain tetrabenazine's efficacy in reducing dyskinetic movements but would be safer and better tolerated. 13 Valbenazine is among 3.6% of patients randomised to deutetrabenazine (any dose) vs 3.1% for placebo, yielding a NNH of 189 (not significant). The Likelihood to be Helped or Harmed comparing success (AIMS response) vs discontinuation because of an adverse event is 27. The most common adverse reactions (that occurred in ≥4% of deutetrabenazinetreated patients with TD and greater than placebo) were nasopharyngitis and insomnia, with NNH values of 50 (not significant) and 34 (95% CI 18-725), respectively.
Conclusions:
Deutetrabenazine is the second FDA-approved agent specifically indicated for the treatment of TD. Head-to-head comparisons with other VMAT2 inhibitors among patients with TD in the "real world" are needed.
Review criteria
The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/ and http://www.
clinicaltrials.gov, for the search terms "deutetrabenazine" OR "SD-809", and by also querying the EMBASE (Elsevier) commercial database for clinical poster abstracts, and by asking the manufacturer for copies of posters presented at congresses. Product labelling provided additional information.
Message for the clinic
Deutetrabenazine is the second FDA-approved agent specifically indicated for the treatment of tardive dyskinesia (TD).
Deutetrabenazine dose is determined individually for each patient based on reduction of TD and tolerability. The recommended starting dose of deutetrabenazine for TD is 6 mg BID, administered with food, and can be increased at weekly intervals in increments of 6 mg per day to a maximum recom- as defined by a rating of "much improved" or "very much improved" on the Clinical Global Impression of Change, was 46%
for deutetrabenazine (pooled dose groups 12 and 18 mg BID) vs 26% for placebo, yielding a NNT of 5 (95% CI [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ; the percentage of responders as defined by an improvement in
Abnormal Involuntary Movement Scale (AIMS) severity score (sum of items 1-7) of 50% or more, was 34% for deutetrabenazine (pooled dose groups 12 and 18 mg BID) vs 12% for placebo, yielding a NNT of 5 (95% CI [3] [4] [5] [6] [7] [8] [9] [10] [11] . Pooling the data across both short-term studies, NNT for AIMS response for | 3 of 17 CITROME one such alternative; valbenazine itself has low VMAT2 activity (Ki ~ 150 nM) but is metabolised to a highly selective VMAT2 inhibitor.
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The other alternative is deutetrabenazine, the subject of this review.
The aim of this review is to synthesise the available data regarding the efficacy and safety of deutetrabenazine for the treatment of TD and to place this new medication into clinical perspective.
| DATA SOURCES
Clinical trial information was accessed by online query on 12 August 2017 using the US National Library of Medicine's PubMed resource (http://www.ncbi.nlm.nih.gov/pubmed/) and the US ClinicalTrials.
gov registry (http://www.clinicaltrials.gov) using the search terms "deutetrabenazine" OR "SD-809", and by also querying the EMBASE 
| STUDY SELECTION
Query of the PubMed literature database identified 15 records, of which 2 were original reports of clinical trial data. 15,16 EMBASE provided a total of 115 records and upon elimination of duplicates, additional relevant abstracts regarding deutetrabenazine for the treatment of TD from congress presentations were identified.
17-29
The corresponding posters from congress presentations were made available by the manufacturer, together with additional posters not routinely abstracted in EMBASE such as from presentations at the annual meetings of the American Psychiatric Association and the US Psychiatric and Mental Health Congress. [30] [31] [32] An additional document from a corporate presentation by Auspex Pharmaceuticals was also accessed. 33 The FDA Drug Approval Package for deutetrabenazine for the treatment of chorea associated with Huntington's disease was another source of information, particularly regarding pharmacokinetic and pharmacodynamic data.
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A total of 6 trials for deutetrabenazine are registered at ClinicalTrials.gov, of which 3 are in patients with TD and all are sponsored by the manufacturer (Table 1) ; completed randomised Phase II and III clinical trials for deutetrabenazine in persons with TD for which results are available are listed in Table 2 . NNT and a high NNH when comparing it with another intervention; a low NNT and a high NNH would mean one is more likely to encounter a benefit than a harm. A rule of thumb is that single digit NNTs for efficacy measures suggests that the intervention has potentially useful advantages, and that double digit or higher NNHs for adverse outcomes indicate that the intervention is potentially tolerable. 37 Where possible and applicable, for each NNT or NNH, 95% confidence intervals (CI) are computed. For where the NNT or NNH is not statistically significant at the P < .05 threshold, the notation "ns" is shown and avoids the display of discontinuous confidence intervals that include "−∞" and "+∞". 35 
| DATA EXTRACTION

| DATA SYNTHESIS
| Pharmacodynamics, pharmacokinetics and metabolism
Deutetrabenazine is a racemic mixture of RR and SS deutetrabenazine. 1 The major circulating metabolites of deutetrabenazine, the therapeutic doses of deutetrabenazine vs placebo was 7 Compared with hydrogen, which has 1 electron and 1 proton, deuterium has 1 electron and both a neutron and a proton in its nucleus, and thus has twice the molecular weight. With deuterium substitution, there is no change in the shape, size, charge or target pharmacology of small molecules. 33, 43 However, because a carbon-deuterium chemical bond is stronger than a carbon-hydrogen bond, deuterium substitution slows down drug metabolism. 44 This attenuation of metabolism can improve tolerability by reducing adverse events related to peak plasma concentrations, a problem that had been noted with tetrabenazine.
Other potential advantages of a deuterated compound include less frequent dosing, reduced interpatient variability in drug metabolism, reduced drug interactions and reduced need for genotyping (the latter a requirement when dosing tetrabenazine beyond 50 mg/day). • Participants were randomly assigned 1:1 to twice-daily placebo (N = 59) or deutetrabenazine (N = 58); after randomisation, study drug was started at 6 mg BID and titrated weekly by 6 mg/d, if required, for up to 6 weeks until adequate dyskinesia control was achieved, a significant AE occurred, or the maximal allowable dose was reached (48 mg/d; 36 mg/d in subjects receiving a strong CYP2D6 inhibitor); this was followed by 6 weeks at the same dose (maintenance phase); at the end of the titration period, the mean total daily dose was 38.8 mg/d; completion rates were ~90% • The primary end-point was change in AIMS score (items 1 through 7) from baseline to Week 12 as assessed by 2 blinded central video raters who were movement disorders experts • LS mean change from baseline to Week 12 in AIMS score was −3.0 for the deutetrabenazine group vs −1.6 for the placebo group ( ; after randomisation, subjects underwent dose escalation through Week 4, during which the dose of study drug was increased in increments of 6 mg/d until the randomised dose was achieved; subjects received their randomised dose over the maintenance period for the next 8 weeks of the study but during this period, patients who experienced a clinically significant AE could have their dose decreased once by 6 mg/d; completion rates were ~90% • The primary end-point was change in AIMS score (items 1 through 7) from baseline to Week 12, as assessed by blinded central video rating, for the modified intent to treat population, consisting of all patients who had a centrally read baseline AIMS score ≥6, received study drug, and had at least 1 postbaseline AIMS assessment • LS mean change from baseline to Week 12 in AIMS score was -3.3 in the deutetrabenazine 18 mg BID group, -3.2 in the 12 mg BID group and -2.1 in the 6 mg BID group, vs -1.4 for the placebo group; treatment differences vs placebo and 95% CIs were -1.9 (-3.09 to -0.79; P = .001; Cohen's d = 0.61), -1.8 (-3.00 to -0.63; P = .003; Cohen's d = 0.57) and -0.7 (-1.84 to 0.42; P = .217; Cohen's d = 0.22), respectively • There were no single AEs for deutetrabenazine (all doses pooled) with incidence ≥5% and greater than that observed for placebo; discontinuation rates because of AEs were 4.1% for deutetrabenazine (all doses pooled) vs 2.8% for placebo AE, adverse event; AIMS, abnormal involuntary movement scale; CI, confidence interval; LS, least squares a
ClinicalTrials.gov accessed 12 August 2017
The α-HTBZ and β-HTBZ metabolites of deutetrabenazine are substrates for CYP2D6. The effect of CYP2D6 inhibition on the pharmacokinetics of deutetrabenazine and its metabolites was studied in 24 healthy subjects following a single 22.5 mg dose of deutetrabenazine given after 8 days of administration of the strong CYP2D6 inhibitor paroxetine 20 mg daily. 1, 34 Systemic exposure of α-HTBZ was 1.9-fold higher and β-HTBZ was 6.5-fold higher, resulting in approxi- QTcF >30 msec. 26 With tetrabenazine, one subject experienced a QTcF >450 msec but no subjects had an increase in QTcF >30 msec.
In the fixed-dose, placebo-controlled pivotal study of deutetrabenazine, 16 mean QTcF values at baseline were similar between the groups; in patients included in the safety population with normal QTcF at baseline (n = 279), the incidence of abnormal QTcF values (>450 ms)
postbaseline was 13% in placebo compared with 10%, 4% and 6% in the deutetrabenazine 6 mg BID, 12 mg BID and 18 mg BID groups, respectively. Table 2 for a summary.
19
| Efficacy in clinical trials for tardive dyskinesia
| Overview
| NCT02195700 (ARM-TD)
In the 12-week flexible-dose trial by Fernandez, HH et al, Categorical outcomes are outlined in Table 3 , with 23.2% of deutetrabenazine-treated patients meeting the criterion for AIMS response (≥50% reduction in AIMS dyskinesia score from baseline), compared with 17.5% for those treated with placebo, resulting in a T A B L E 3 Deutetrabenazine for tardive dyskinesia: categorical outcomes from the available acute double-blind randomised trials 15, 16 and pooled, displayed as n/N (%) Response defined as a ≥50% reduction from baseline in AIMS dyskinesia score (sum of AIMS items 1-7).
b
Response defined as a score of 1 or 2, ie "very much improved" or "much improved." A negative value for NNT occurs where the rate of the benefit is higher for placebo than for deutetrabenazine; a negative value for NNH occurs when the rate of the harm is higher for placebo than for deutetrabenazine.
e If the 6 mg BID dose is not excluded from the pooled calculation of discontinuation because of an adverse event (shown in Table 5 ), the NNH estimate is 189 (ns) and the LHH is 27. 
NNT of 18 (ns)
. CGIC response rates yielded a NNT of 13 (ns), and PGIC response rates yielded a NNT of 8 (ns).
| NCT02291861 (AIM-TD)
In the 12-week fixed-dose study by Anderson et al, 16 male and female subjects, aged 18-80 years, with a TD diagnosis (criteria the same as in the earlier study), and with a total AIMS score of 6 or more were eligible to participate. This AIMS criterion was assessed at both screening and baseline by the investigator and confirmed by an independent movement disorder expert via central video rating. As in the earlier study, patients with underlying psychiatric illness were required to be stable, with no change in psychoactive medication. Exclusion criteria were similar to that of the earlier study. Deutetrabenazine was efficacious both in patients receiving and those not receiving concomitant dopamine receptor blocking agents at baseline. 16, 23 In the analysis of cumulative proportion of AIMS responders, results also favoured deutetrabenazine 12 and 18 mg BID (Table 4) . A negative value for NNT occurs where the rate of the benefit is higher for placebo than for deutetrabenazine.
| 9 of 17 CITROME a treatment difference on the CGIC compared with placebo (leastsquares mean treatment difference: 12 mg BID, -0.6; 18 mg/d, -0.5).
There was high correlation between site-rated AIMS scores and CGIC ratings (correlation coefficient: 0.718, 95% CI 0.643-0.777). 21 There was no statistically significant difference between deutetrabenazine vs placebo on the PGIC or mCDQ-24 score, although numerical advantages were evident for 12 and 18 mg BID over placebo. 16, 17 Categorical outcomes are outlined in Table 3 , with 33.7% of deutetrabenazine-treated patients receiving 12 or 18 mg BID meeting the criterion for AIMS response (≥50% reduction in AIMS dyskinesia score from baseline), compared with 12.1% for those treated with placebo, resulting in a NNT of 5 (95% CI 3-11). CGIC response rates yielded a NNT of 5 (95% CI 3-19), and PGIC response rates yielded a NNT of 9 (ns). 
| Pooled short-term data
Pooling together the efficacy data from the 2 short-term studies and using the threshold of 50% for AIMS reduction as a definition of response, deutetrabenazine (excluding the 6 mg BID dose) resulted in a responder rate of 30% for deutetrabenazine vs 15% for placebo, yielding a NNT of 7 (95% CI 4-18). Similarly, CGIC treatment success rates were 47% vs 33%, respectively, yielding a NNT of 8 (95% CI 4-45); excluding subjects with a baseline AIMS <6 in the phase II/III study from the calculation yields a difference of 48% vs 30%, yielding a NNT of 6 (95% CI 4-16). As reported in a poster presentation of pooled CGIC results (excluding deutetrabenazine 6 mg BID, and including only those subjects with a baseline AIMS score ≥6 from the Phase II/III study), a shift analysis of all CGIC ratings demonstrated that patients treated with deutetrabenazine had greater improvement than that observed with placebo; moreover, mean CGIC score was significantly more improved in patients treated with deutetrabenazine than in those treated with placebo at Week 12 (treatment difference: −0.4). 24 As per Table 4 , although PGIC treatment response was not statistically significantly different between deutetrabenazine vs placebo in the individual studies, PGIC treatment success for pooled data demonstrated a statistically significantly difference in favour of deutetrabenazine, with rates of 42.5% for deutetrabenazine vs 30% for placebo, yielding a NNT of 9 (95% CI 5-145); excluding subjects with a baseline AIMS <6 in the phase II/III study from the calculation yields a difference of 43% vs 30%, yielding a NNT of 8 (95% CI 4-56). As reported in a poster presentation of pooled PGIC results (excluding deutetrabenazine 6 mg BID, and including only those subjects with a baseline AIMS score ≥6 from the Phase II/III study), among 145 patients with a psychotic disorder, 45% were "much improved" or "very much improved" at Week 12 with deutetrabenazine compared with 37% for patients receiving placebo, 22 yielding a NNT of 13 (ns). In contrast, a larger deutetrabenazineplacebo difference was evident among 95 patients with a mood disorder where 48% of the patients receiving deutetrabenazine were "much improved" or "very much improved" compared 27% for those receiving placebo, resulting in a NNT of 5 (95% CI 3-50). This disparity between PGIC results for psychotic disordered patients vs mood disordered patients suggests that TD patients with underlying mood disorders were more likely to perceive treatment success with deutetrabenazine than with placebo; this may be related to better insight into TD, something that is often lacking in persons with schizophrenia.
Effect of deutetrabenazine by body region score of the AIMS from pooled data from both short-term trials were presented in a poster. 20 Deutetrabenazine (all doses pooled excluding 6 mg BID and including only those subjects with a baseline AIMS score ≥6 from the Phase II/III study) was compared with placebo. Pooled analysis of change in AIMS score at 
| Long-term data
Additional efficacy data have been presented from an open-label longterm study. 31 Patients who completed the 12-week short-term studies were included. All patients restarted/started deutetrabenazine 6 mg BID, titrating up to a maximum total daily dose of 48 mg/day. The study com- of open-label treatment, the proportion of patients who achieved treatment success was 58% as measured by the CGIC and 53% as measured by the PGIC; by Week 54, a higher proportion were categorised as responders: 72% as per the CGIC and 59% as per the PGIC.
| Tolerability and safety in clinical trials for tardive dyskinesia
| NCT02195700 (ARM-TD)
In the 12-week flexible-dose trial by Fernandez et al, 15 several tolerability and safety assessments were reported. For the deutetrabenazine and placebo groups, there were relatively low rates of dose reductions, suspensions and study withdrawals because of adverse events, as presented in Table 5 . Comparing deutetrabenazine with placebo, NNH for dose reduction was 19 (ns). Dose suspensions and discontinuations attributable to an adverse event were more commonly observed in patients randomised to placebo, yielding "negative" NNH estimates for deutetrabenazine vs placebo. The most common adverse events are presented in Table 6 . Events more commonly observed with deutetrabenazine than with placebo were somnolence, insomnia, akathisia 
| NCT02291861 (AIM-TD)
The fixed-dose study by Anderson et al 16 provides additional tolerability and safety data by dose. As observed in the prior study, there were relatively low rates of dose reductions, suspensions and study withdrawals because of adverse events, as shown in Table 5 .
Comparing deutetrabenazine with placebo, NNH for dose reduction was not calculable for the 6 mg BID dose as the rates were zero. The rates of adverse events leading to dose reduction were higher for deutetrabenazine 18 mg BID (4.1%, NNH vs placebo 25) than for 12 mg BID (1.4%, NNH 73). Pooling all doses, the NNH for an adverse event leading to dose reduction was 56 (95% CI . No evidence for a dose-response was evident for dose suspensions or discontinuations because of an adverse event. Pooling all doses of deutetrabenazine, adverse events leading to dose suspension was more commonly encountered for patients randomised to placebo. Discontinuation rates because of adverse events were low: 4.1% for patients randomised to deutetrabenazine (all doses pooled) vs 2.8% for placebo, yielding a NNH of 78 (ns). The most common adverse events are listed in Table 6 
| Pooled short-term data
Pooled safety and tolerability outcomes are summarised in Tables 5 and   6 by combining the common elements from the two reported shortterm studies. 15, 16 Overall, adverse events leading to discontinuation was more common with deutetrabenazine than with placebo, but if the 6 mg BID dose is excluded from the calculations, the opposite was true (Table 3 ). There were no adverse events that occurred at a rate ≥5% and higher than that for placebo. For those adverse events reported in both studies (and thus allowing pooling of data), adverse events that were more common with deutetrabenazine than placebo were akathisia 
| Long-term data
Interim safety and tolerability data from 54 weeks of exposure in an open-label study have been presented as a poster. 18 As noted earlier, patients who completed the 12-week short-term studies were included. The most common adverse events (by exposure-adjusted T A B L E 5 Deutetrabenazine for tardive dyskinesia: overall tolerability as determined by rates of adverse events leading to dose reduction, dose suspension or discontinuation as reported in the available acute double-blind randomised trials and pooled, displayed as n (%) 
(ns)
(ns) -
(ns)
AE, adverse event; CI, confidence interval; ND, no difference; NNH, number needed to harm; ns, not significant.
a
A negative value for NNH occurs when the rate of the harm is higher for placebo than for deutetrabenazine.
T A B L E 6 Deutetrabenazine for tardive dyskinesia: rates of adverse events as reported in the available acute double-blind, randomised trials 15, 16 and pooled, displayed as n (%) Threshold is incidence of adverse events experienced by >4% of subjects in either treatment group, and greater for deutetrabenazine than that observed with placebo, or if data are available for this study and had met the threshold for reporting in Anderson KE, et al. Threshold is incidence of adverse events experienced by > 4% of subjects in any treatment group, and greater for deutetrabenazine (when doses pooled) than that observed with placebo, or if data are available for this study and had met the threshold for reporting in Fernandez HH, et al. A negative value for NNH occurs when the rate of the harm is higher for placebo than for deutetrabenazine. | 13 of 17 CITROME incidence rates, expressed as incidence/patient-years) were anxiety (0.12), somnolence (0.11), depression (0.11), headache (0.10), diarrhoea (0.08), nasopharyngitis (0.08) and fatigue (0.07). Neuropsychiatric adverse event rates were low and >90% were mild to moderate in severity. The exposure-adjusted incidence rate for discontinuation because of an adverse event was low (0.08). Exposure-adjusted incident rates for suicidality were 0.02; for akathisia and restlessness, 0.02; and for Parkinsonism, 0.05.
| Additional safety information as noted in the product label
The product label for deutetrabenazine is free of any boxed bolded warnings relevant to TD; the bolded boxed warning that existed in the initial product label for deutetrabenazine prior to approval for TD has been rewritten to read "Depression and Suicidality in Patients with There are marked differences in the list of adverse reactions that have been observed in patients treated for Huntington's disease compared with patients treated for TD. The two 12-week, randomised, parallel group, double-blind, placebo-controlled studies 15, 16 were the basis for the adverse reaction reporting contained in product labelling for TD and this is summarised in Table 7 . NNH values range from 34 to 100. The most common adverse reactions (that occurred in ≥4% of deutetrabenazine-treated patients with TD and greater than placebo)
were nasopharyngitis and insomnia. The largest difference in incidence rates between deutetrabenazine vs placebo was observed for insomnia (4% vs 1%), resulting in a NNH value of 34 (95% CI 18-725).
The product label notes that the available data on deutetrabenazine in pregnant women are insufficient to determine if there is a drug-associated risk. There are no data on the presence of deutetrabenazine or its metabolites in human milk, the effects on the breastfed infant or the effects of the drug on milk production.
| Administration, optimal dose and drug-drug interactions
Deutetrabenazine tablets are currently available in 3 different strengths:
6, 9 and 12 mg. Numerators were not reported and were estimated using the reported percentages when calculating the NNH and 95% CIs. CI, confidence interval; NNH, number needed to harm; ns, not significant.
T A B L E 7 Deutetrabenazine for tardive dyskinesia: adverse events associated with the use of deutetrabenazine (incidence of ≥2% and deutetrabenazine incidence greater than placebo) that occurred during acute therapy (up to 12 weeks), percentage of subjects, and number needed to harm vs placebo and 95% confidence intervals, percentages as reported in product labelling Clinical studies of deutetrabenazine did not include sufficient numbers of persons aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of possible hepatic, renal and cardiac dysfunction, and possible drug-disease and drugdrug interactions. The use of deutetrabenazine in persons with hepatic impairment is contraindicated because in a study with tetrabenazine in patients with hepatic impairment, there was a substantial increase in exposure to tetrabenazine and its active metabolites. No clinical studies have been conducted to assess the effect of renal impairment on the pharmacokinetics of deutetrabenazine.
| Likelihood to be helped or harmed
To be effective in real-world clinical practice, medications must be efficacious enough, tolerable enough and the patient needs to take it consistently enough. Likelihood to be helped or harmed (LHH)
can be calculated to quantify trade-offs between efficacy and tolerability, and is simply the ratio of NNH to NNT. (Table 3) , indicating the medication is potentially useful in routine clinical practice. 37 Pooling all doses (including 6 mg BID) across both short-term studies, discontinuation because of an adverse event occurred among 3.6% of patients randomised to deutetrabenazine vs 3.1% for placebo, yielding a NNH of 189 (ns). Thus, the LHH comparing success (AIMS response) vs discontinuation because of an adverse event is 189/7, or 27. This can be interpreted as "therapeutic doses of deutetrabenazine would be about 27 times more likely to result in a response than a discontinuation because of an adverse event."
From the product label, the most commonly encountered adverse event with the largest difference from placebo was insomnia, with rates of 4% for deutetrabenazine-treated patients vs 1% for placebo, resulting in a NNH of 34. LHH for response vs insomnia is 34/7, or 5. Thus, a therapeutic dose of deutetrabenazine would be about 5
times more likely to result in a response than an adverse event of insomnia. Adverse events may differ in terms of impact and may not be clinically relevant if the adverse event is mild, time-limited or easily managed. A caveat is that different patients carry different
propensities to experience different adverse events or to achieve a therapeutic response.
| DISCUSSION
Although current evidence supports a lower risk for TD with secondgeneration antipsychotics than with first-generation antipsychotics, TD remains a significant treatment issue. 6 Deutetrabenazine is the second FDA-approved medication specifically indicated for the treatment of TD, and will provide an additional option when other strategies for managing TD such as switching or discontinuing the antipsychotic medication are not feasible or effective. 47 Deutetrabenazine for TD appears well-tolerated, with a favourable LHH ratio for response vs discontinuation because of an adverse event. The most common adverse event with the largest difference in incidence vs placebo is insomnia, but the rates are low (4% vs 1%), yielding a NNH of 34, suggesting that this effect will not be a substantial obstacle to using deutetrabenazine.
Tetrabenazine has been used "off-label" for the treatment of TD. can be acquired at a better negotiated rate than the other one for any given health plan.
Limitations to this review include that the brief (12 weeks) durations of the two available controlled studies of deutetrabenazine limit the sensitivity of calculating NNH for delayed adverse outcomes, and the relatively small sample sizes of the studies limit sensitivity of calculating NNH for uncommon adverse outcomes and subpopulation effects (including more precisely determining differential effects based on underlying diagnosis and the concomitant antipsychotic(s) prescribed). There is a need for controlled chronic efficacy and safety/tolerability data. The definition of AIMS response as a 50% reduction from baseline is a more rigorous criterion to define treatment response than thresholds of 25% or 30% used by some researchers in prior studies; 51 however, this remains different from a definition of response (or remission), whereby the AIMS dyskinesia score would be lower than an agreed upon clinically meaningful threshold. 37 Moreover, when treating individual patients, an AIMS dyskinesia score of 7 has very different implications when it is based on a score of "1" across all 7 items vs a score of "3" on 2 items and a "1" on a third. In the latter patient, more urgent efforts will need to be made to get those individual item scores of "3" down to as low as possible. Additional analyses examining centrally rated AIMS response and correlating it with other efficacy outcomes such as the clinician-rated CGIC and the patient-rated PGIC would be of interest. Other limitations are that some of the data are from posters presented at congresses, and that these data should be considered preliminary pending the publication of peer-reviewed reports. 
